Our data support the conclusion that IRF4 plays an essential role in BCL2‐induced upregulation of SOX9 expression, and targeting IRF4 may represent a promising therapeutic strategy to cure relapsed and refractory DLBCL. Here, IRF4 is linked to diffuse large B-cell lymphoma.